PharmaVoice

Stay informed with the latest pharma industry news and insights by signing up for PharmaVoice. Explore all our free newsletter options here: https://lnkd.in/gP2m_c7J

Bristol Myers Squibb could soon see some headwinds for its blockbuster leukemia drug #Sprycel as the first generic is expected to hit the market in September. #pharma #patents #generics https://lnkd.in/euuBts4S

Pharma executives and lobbyists have long sought to shift the blame for U.S. drug costs to the industry’s price-negotiating middlemen known as pharmacy benefit managers. “Last year, about 80% of our insulin list prices went to paying fees and rebates to companies who didn’t invent, develop, manufacture nor study the medicine,” Eli Lilly and Company CEO Dave Ricks said at the May 2023 congressional hearing. Now, a new FTC report might provide drugmakers some validation. #pharma #PBM Federal Trade Commission National Community Pharmacists Association (NCPA) Douglas Hoey Pharmaceutical Care Management Association (PCMA) https://lnkd.in/dyct-8Pd

With more Americans taking obesity medications, adjacent businesses are offering supportive services to offset side effects, collect data and foster new health benefits. #GLP1 #obesity #semaglutide #ozempic Ivim Health Xevant Nestlé Health Science Dandelion Health https://lnkd.in/eMkCn3w5

Recent history suggests an Alzheimer’s approval doesn’t necessarily translate to market triumph. Perhaps for Eli Lilly and Company’s Kisunla, this time could be different. “Any new treatment in the Alzheimer’s area is providing some hope to that community,” says Jayne Hornung, chief clinical officer at MMIT (Managed Markets Insight & Technology). #ALZ #donanemab Michael Gibney https://lnkd.in/exg-XQ8T

The FDA has taken another tangible step to boosting #diversity in clinical trials. The agency recently released a long-awaited draft guidance revealing more details about how sponsors can create Diversity Action Plans to enroll trial participants who more fully represent the people using products once they hit the market. Rohit Nambisan Julie Ozier https://lnkd.in/exjw42Ra

Neuroscience pipelines are reawakening as biotechs prove to the pharma giants that the field is still worth the investment. “We’re seeing a resurgence of interest in central nervous system disorders, and for folks that have been in that space for some time, we’re delighted to see investment coming back," says Gene Kinney, CEO of Prothena Corporation. #biotech #brain #CNS Karuna Therapeutics Bristol Myers Squibb GSK Celgene Pfizer Novartis AstraZeneca https://lnkd.in/gUpTtiC7

In pharma and biotech, success is measured in decades. For Geron Corporation's blood #cancer treatment, Rytelo, the road to approval was 33 years, including “about 20 years of development in patients,” according to Faye Feller, Geron's chief medical officer. “We’ve had a strong belief in bringing this mechanism to patients that has really persisted,” she told PharmaVoice. #drugdevelopment #oncology #firstinclass https://lnkd.in/e247ACPF

Weight loss market leaders Eli Lilly and Company and Novo Nordisk are warning patients and healthcare providers about the risks associated with knockoff versions of their popular #obesity meds — and taking legal action. #ozempic #mounjaro #GLP1 #wegovy #zepbound https://lnkd.in/eSWdKPHC